In this study, we found that the acetylation level of EZH2 in drug-resistant cells was significantly lower than parental sensitive cells, suggesting that deacetylase inhibitors may be a new strategy to reverse EGFR-TKI acquired resistance in NSCLC. This evidence concerns the gene EZH2 and non-small cell lung carcinoma.